Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-targeting in vivo CAR-macrophage therapy
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This investigational *in vivo* chimeric antigen receptor macrophage (CAR-M) therapy is being developed by Carisma Therapeutics in collaboration with Moderna for the treatment of hepatocellular carcinoma (HCC). The therapy utilizes mRNA technology delivered via lipid nanoparticles (LNPs) to genetically reprogram endogenous macrophages and monocytes directly within the patient's body. The mRNA encodes a chimeric antigen receptor (CAR) specific to Glypican-3 (GPC3), a tumor-associated antigen highly expressed in HCC. Once expressed, these CAR-macrophages are designed to recognize and destroy GPC3-positive tumor cells through phagocytosis and the induction of a broader anti-tumor immune response. This off-the-shelf approach aims to circumvent the manufacturing complexities and costs associated with traditional *ex vivo* cell therapies.
- Other names
- in vivo CAR-M GPC3Carisma/Moderna GPC3 mRNA-LNPIn Vivo CAR-Macrophage: GPC3+ Solid Tumors
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-targeting in vivo CAR-macrophage therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-targeting in vivo CAR-macrophage therapy.